Morning Buzz: Neuralstem (CUR), Celladon Corporation (CLDN), Real Goods Solar (RGSE), ARCA biopharma (ABIO)

Neuralstem, Inc. (CUR) is a big mover this pre-market session, as its shares are up more than 11%. The surge came after the company, which uses neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, reported preclinical data on its genetically modified HK532-IGF-1 stem cells. Neuralstem said that mice with an animal model of Alzheimer’s disease (AD), transplanted with HK532-IGF-1 cells in the peri-hippocampus, performed better on hippocampal-dependent behavioral tasks than untreated mice, demonstrating both enhanced learning cognitive processes and memory consolidation. Results indicate that HK532-IGF-1 transplantation can impact learning and memory deficits, as well as Alzheimer’s pathology.

Celladon Corporation (CLDN) shares plunged 43.18% in early trade Friday, as the company confirmed plans to suspend further research or development of its Mydicar program, and its other pre-clinical programs including the Stem Cell Factor gene therapy and SERCA2b small molecule programs.

Real Goods Solar, Inc. (RGSE) lost as much 18.35% to $3.56 Friday morning after announcing a public offering of $5 million units consisting of shares of common stock and warrants at $3.65 per unit.

Each unit consists of one share of Class A common stock and a warrant to purchase 0.3 share of Class A common stock at an exercise price of $4.20 per share. The warrants are exercisable beginning six months after issuance and for a period of five years thereafter.

In a 13G filing on ARCA biopharma, Inc. (ABIO), RA Capital Management and Venrock Healthcare Capital Partners disclosed a 9.0% and 17.1%, respectively, passive stake in the biopharmaceutical company.

ABIO shares recently gained 8c to $1.05. The stock is down 32.65% year-over-year and has gained roughly 2% year-to-date. In the past 52 weeks, shares of Charlotte, North Carolina-based firm have traded between a low of $0.65 and a high of $1.65.

ARCA biopharma, Inc. closed Thursday at $0.97. The name has a current market cap of $20.56 million.

Be the first to comment

Leave a Reply

Your email address will not be published.


*